Time-Sensitive Class Action Alert for Shareholders of Geron Corporation
Attention shareholders of Geron Corporation (NASDAQ: GERN): if you acquired shares during the specified class period, please take note of an important announcement from the Gross Law Firm.
Shareholder Engagement for Class Action
The Gross Law Firm is reaching out to individuals who purchased shares of GERN. If you're among these investors, you may have the opportunity to be appointed as a lead plaintiff in this class action. However, participating as a lead plaintiff is not essential to recover any potential losses incurred due to the events described in this notice.
Details Pertaining to the Class Period
CLASS PERIOD: This class action concerns share purchases made between February 28, 2024, and February 25, 2025. It is imperative for eligible shareholders to act quickly.
Allegations Against Geron Corporation
According to the filed complaint, investors were provided with material information that painted an overly optimistic picture regarding the drug Rytelo (imetelstat). The defendants had expressed confidence in the company’s capacity to address a significant unmet medical need and to successfully launch Rytelo to target first-line ESA eligible patients. However, they failed to adequately communicate the associated risks and competition that would impact sales, as well as the burden of ongoing monitoring required for Rytelo.
Market Reactions to Financial Disclosure
On February 26, 2025, Geron released its financial results for the fourth quarter of fiscal 2024, revealing disappointing growth figures for Rytelo. The company cited various factors for this stagnation, including competition and a lack of market awareness. This announcement led to a steep decline in the share price—from $2.37 to $1.61, a drop of over 32.07% in just one trading day.
Crucial Deadline for Shareholders
DEADLINE: May 12, 2025 is the final date for shareholders to register their interest in participating in the class action against Geron Corporation. Don’t hesitate to secure your position; it’s crucial that affected shareholders get involved at this stage.
Next Steps for Interested Shareholders
Once you express your interest as a shareholder of GERN within the previously mentioned timeframes, you will be enrolled in a portfolio monitoring tool. This will provide you with ongoing updates throughout the progression of this case. It is free of charge to participate, with no obligations on your part.
Why Choose the Gross Law Firm?
The Gross Law Firm is a recognized national leader in class action cases. Our focus is on safeguarding the rights of investors affected by deceptive practices and fraud. We strive for accountability among corporations to ensure adherence to ethical business standards, supporting our clients in recovering losses stemming from misleading information.
Contact Information
For inquiries, reach out to the Gross Law Firm's office located at: 15 West 38th Street, 12th Floor, New York, NY 10018. You can get in touch via phone at (646) 453-8903. For further communications, please email us directly.
Frequently Asked Questions
What is the class action about?
The class action pertains to shareholder losses associated with Geron Corporation's misrepresentations regarding the performance of their drug Rytelo.
Who can participate in the class action?
Any investor who purchased Geron shares during the specified class period can register for participation.
What are the expected next steps after registration?
Registered shareholders will receive continuous updates regarding the status of the class action and their potential eligibility for recovery.
Is there a cost to participate in the class action?
No, there is no cost to register or to participate in the action.
Why is the deadline important?
The May 12, 2025 deadline is critical for ensuring your eligibility to recover losses should the class action succeed.
